CytoGenix Announces Hiring of New Chief Financial Officer.

HOUSTON -- CytoGenix, Inc. (OTCBB:CYGX) announced today that Greg S. Taylor has joined CytoGenix as Chief Financial Officer and Vice President for Finance and Administration effective September 1, 2007. Ms. Pam Schertz who has ably served the Company as interim CFO will remain in the position of Controller.

Mr. Taylor has almost 20 years of investment banking, venture capital, corporate advisory and entrepreneurial experience and has completed over $2BB in transactions. He has previous management experience as both a CEO and CFO. Mr. Taylor is currently Managing Director of Monterey Capital Partners, a private equity investment firm. Previously he served as a VP with the investment banking division of Sumitomo Trust and Banking and with Bunker Hill Associates, a merchant-banking firm. Mr. Taylor began his career as a CPA with Ernst and Whinney, a national public accounting firm.

Mr. Taylor has served on the boards of directors of several private companies and charitable organizations. He received a Bachelor of Business Administration and a Masters of Taxation both from Baylor University.

Malcolm Skolnick, CEO, comments, "I have had the opportunity to work with Mr. Taylor as he assisted us with Sarbanes-Oxley compliance issues and have developed great respect for both his integrity and competence. His business experience and insight will greatly increase the strength of our management team and should help us in our financing efforts as well as our business plan advancement."

Greg Taylor states, "I am excited to join CytoGenix, Inc. I believe the company's technology platforms along with its collaborative research and product pipeline present a tremendous opportunity for growth in shareholder value. The company is pursuing a number of funding opportunities that should provide the resources necessary to significantly advance its business plan."

CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary synDNA(TM) production and ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of biologically active DNA that can be made faster and cleaner than production using traditional fermentation methods and has developed a novel expression vector that enables production of ssDNA sequences inside the cell. CytoGenix currently holds 11 granted patents and about 49 international or US pending patent applications claiming methods and materials in connection with these platform technologies.

SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology can be found on the website at www.cytogenix.com.